<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120675</url>
  </required_header>
  <id_info>
    <org_study_id>43-Α/24-10-2018</org_study_id>
    <nct_id>NCT04120675</nct_id>
  </id_info>
  <brief_title>Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis</brief_title>
  <official_title>The Effects of Early Harvest Extra Virgin Olive Oil on Cognition and Mental Health of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Greek Alzheimer's Association and Related Disorders</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ellis-Farm, Eliama Daily Value Gold (ellis-farm.com)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date, no drug therapy has been approved for primary (PPMS) &amp; secondary (SPMS) progressive&#xD;
      multiple sclerosis. The urgent need to find new therapies - if possible with minimal side&#xD;
      effects - led us to the search for the potential therapeutic effects of early harvest olive&#xD;
      oil. The positive effect of phenol-rich, flavonoid and lignin-based olive oil on the&#xD;
      modification of intestinal microbe populations and their by-products of metabolism is well&#xD;
      known, such as the extent of gut-associated lymphoid tissue immune-stimulation due to&#xD;
      antioxidants, anti-inflammatory and immunoregulatory properties. The aim of this Greek,&#xD;
      Randomized Clinical Trial, is to evaluate the effect of Early Harvest Extra Virgin Olive Oil&#xD;
      on cognition and mental health of patients diagnosed with PPMS or SPMS. The patients will be&#xD;
      evaluated once at the beginning of treatment, after 6 months of treatment and after twelve&#xD;
      months of treatment, in order to specify the eficacy of extra virgin olive oil in holistic&#xD;
      treatments for SPMS and PPMS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Randomized Clinical Trial. Primary Purpose: Prevention OBJECTIVES OF THE TRIAL&#xD;
      The objectives of this study are:To investigate the efficacy of Early Harvest EVOO as a&#xD;
      disease course modifying treatment for primary (PPMS) or secondary (SPMS) progressive&#xD;
      multiple sclerosis in a phase III randomized controlled clinical trial study in objective&#xD;
      measurements in patients with primary (PPMS) or secondary (SPMS) progressive multiple&#xD;
      sclerosis.&#xD;
&#xD;
      STUDY DESIGN This is a Greek, randomized controlled study group of Early Harvest EVOO to a&#xD;
      control group, in which the patients will receive only their symptomatic medication.&#xD;
      Qualifying patients will be randomly assigned to receive 50mL of Early Harvest EVOO or not on&#xD;
      a daily basis for 24 months. Patients undergo assessments at baseline, 6 and 12 months +/- 7&#xD;
      days after beginning treatment.&#xD;
&#xD;
      Duration: The total study duration will be 12 months. Patients will receive study&#xD;
      interventions for 12 months.&#xD;
&#xD;
      Number of Subjects 30 subjects total will be enrolled; 20 in the experimental group (Early&#xD;
      Harvest EVOO); 10 in the Control group&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2018</start_date>
  <completion_date type="Actual">June 6, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Greek Verbal Learning Test (GVLT)- Assessment of auditory and verbal memory</measure>
    <time_frame>baseline, 6 and 12 months</time_frame>
    <description>Changes in Greek Verbal Learning Test (GVLT) score. Score range:0-80. Higher score indicates better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Visuospatial Memory Test (BVMT)- Assessment of visual and spatial memory</measure>
    <time_frame>baseline, 6 and 12 months</time_frame>
    <description>Changes in Brief Visuospatial Memory Test (BVMT) score. Score range:0-36. Higher score indicates better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symbol Digit Modalities Test (SDMT)- Assessment of processing speed and working memory</measure>
    <time_frame>baseline, 6 and 12 months</time_frame>
    <description>Changes in Symbol Digit Modalities Test (SDMT) score. Score range:1-110. Higher score indicates better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived Deficits Questionnaire (PDQ)- Measurement of subjective cognitive deficits</measure>
    <time_frame>baseline, 12 and 24 months</time_frame>
    <description>Changes in Perceived Deficits Questionnaire (PDQ) score. Score range:0-80. Lower score indicates better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frontal Assessment Battery (FAB)- Assessment of frontal deficits</measure>
    <time_frame>baseline, 6 and 12 months</time_frame>
    <description>Changes in Frontal Assessment Battery (FAB) score. Score Range:0-18. Higher score indictaes better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Depression Scale (BDI)- Measurement of depressive symptoms</measure>
    <time_frame>baseline, 6 and 12 months</time_frame>
    <description>Changes in Beck Depression Scale (BDI) score. Score range:0-63. Lower scores indicate better outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mental Health Inventory (MHI)- Measurement of emotional condition and mental health problems</measure>
    <time_frame>baseline, 6 and 12 months</time_frame>
    <description>Changes in Mental Health Inventory (MHI) score. Score range:0-100. Higher score indicates better outcome</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Group 20 patients on Early Harvest Extra Virgin Olive Oil Aluminum bottle with 500 ml of early harvest extra virgin olive oil (3 tablespoons per day).&#xD;
Dietary Supplement: Early Harvest Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 patients will not receive treatment with Extra Virgin Olive Oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Early Harvest Extra Virgin Olive Oil</intervention_name>
    <description>Participants will take 3 tablespoons on a daily basis</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of primary (PPMS) or secondary (SPMS) progressive multiple&#xD;
             sclerosis&#xD;
&#xD;
          -  EDSS≥ 5&#xD;
&#xD;
          -  No response to any given treatment for MS or interruption due to side effects&#xD;
&#xD;
          -  Progressive aggravation in the disease's progression estimated by: deterioration in&#xD;
             EDSS-plus disability scale, Timed 25-Foot Walk or 9-hole peg test.&#xD;
&#xD;
          -  Progressive aggravation in the disease's progression estimated by: new lesions in MRI&#xD;
             scan and neuropsychological tests&#xD;
&#xD;
          -  Progressive aggravation in patient's neuropsychological status&#xD;
&#xD;
          -  Progressive aggravation in patient's Quality of life, estimated with MuSIQol - Greek&#xD;
             3.01 MS and SF-36&#xD;
&#xD;
          -  Years of education: &gt;= 5&#xD;
&#xD;
          -  Proficient language fluency&#xD;
&#xD;
          -  Have a study partner with 10+ hr/wk contact (can be in person and telephone),&#xD;
             accompanies to visits&#xD;
&#xD;
          -  Compliance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enrollment in other trials or studies not compatible with MSOIL&#xD;
&#xD;
          -  Visual and auditory acuity inadequate for neuropsychological testing&#xD;
&#xD;
          -  History of significant other neurological or psychiatric illnesses or presence of&#xD;
             other diseases precluding enrollment.&#xD;
&#xD;
          -  Use of forbidden medications (listed below)&#xD;
&#xD;
          -  Ferromagnetic implants and devices (including implants or devices held in place by&#xD;
             sutures, granulation or ingrowth of tissue, fixation devices, or by other means) not&#xD;
             eligible for MRI scanning. Brain malformation or other conditions that may complicate&#xD;
             lumbar puncture&#xD;
&#xD;
          -  Any significant or uncontrolled medical condition or treatment-emergent&#xD;
&#xD;
          -  Clinically significant laboratory abnormality&#xD;
&#xD;
        Medications across the study&#xD;
&#xD;
        Excluded Medication:&#xD;
&#xD;
          -  Immunosuppressant or immunomodulating agents, corticosteroids, or investigational&#xD;
             drugs within 3 months of study initiation&#xD;
&#xD;
          -  Antibiotics in general, at least one month prior assessment of specific inflammatory&#xD;
             markers (faecal levels of calprotectin, metabolomic profile, gut microbiota)&#xD;
&#xD;
          -  Use of neuroleptics or within 4 weeks of screening&#xD;
&#xD;
          -  Participation in any other investigational drug study within 4 weeks of screening&#xD;
             (individuals may not participate in any drug study while participating in this&#xD;
             protocol).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>A' Department of Neurology,Aristotle University of Thessaloniki (AUTH)</name>
      <address>
        <city>Thessaloniki</city>
        <state>Macedonia</state>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Magda Tsolaki</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>extra virgin olive oil</keyword>
  <keyword>cognition</keyword>
  <keyword>mental health</keyword>
  <keyword>multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

